Samsung BioLogics Co (XKRX:207940) Margin of Safety % (DCF FCF Based) : N/A (As of Apr. 16, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Samsung BioLogics Co's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Samsung BioLogics Co's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Samsung BioLogics Co's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Samsung BioLogics Co's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Samsung BioLogics Co's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Samsung BioLogics Co's Margin of Safety % (DCF FCF Based) falls into.

Save Embed

;

Save Embed

;

Samsung BioLogics Co Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Samsung BioLogics Co's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Samsung BioLogics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR

Website

https://www.samsungbiologics.com

Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.

Samsung BioLogics Co Headlines

No Headlines